Hemab Therapeutics Holdings, Inc. Research and Development Expense
Hemab Therapeutics Holdings, Inc. (COAG) reported Research and Development Expense of $20.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Hemab Therapeutics Holdings, Inc. research and development expense for the quarter ending 2026-06-30 was $20.34M, a 57.96% increase year-over-year.
- Hemab Therapeutics Holdings, Inc. research and development expense for the quarter ending 2026-03-31 was $19.46M, a 38.01% increase year-over-year.
- Hemab Therapeutics Holdings, Inc. research and development expense for the quarter ending 2025-06-30 was $12.87M.
- Hemab Therapeutics Holdings, Inc. research and development expense for the quarter ending 2025-03-31 was $14.10M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $20.34M 10-Q · filed 2026-08-11 | $39.80M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $19.46M 10-Q · filed 2026-05-21 | |
| 2025-06-30 | $12.87M 10-Q · filed 2026-08-11 | $26.98M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $14.10M 10-Q · filed 2026-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |